Novo Nordisk: A Top 2025 Pick and A New Opportunity

I like shopper intuition.

Thanks, Peter Lynch, for educating us about utilizing our instincts as customers together with megatrends and technical evaluation.

Final evening we went to a cocktail party and the dialog turned to Bowling Inexperienced, Nebraska, the Ozempic capital of the U.S.

On December 2, 2024, I wrote a Each day referred to as, Novo Nordisk, A Love Story.

I wrote, “In accordance with an article within the NY Put up, the food plan medicine have “modified the meals we eat, the methods we have fun, and train, and journey, and costume, and discuss well being and wonder.”

It behooves you to research which corporations are associated to the life-changing traits the article mentions.

I’ve been on this theme since 2023 and now have it as certainly one of my main funding themes for 2025.”

As Novo Nordisk (NYSE:) lately had optimistic information on a trial about its impression on kidney illness, the inventory then gapped up, after which bought off again to main assist.

When people are speaking in regards to the drug at dinner events, and the basics are intact, we get .

It is usually potential, NVO is providing us one other low-risk commerce setup.

The Each day chart exhibits us that even after the hole increased, the value couldn’t maintain above the January 6-month calendar vary.

Nonetheless, the transfer decrease has stored value above the calendar vary low.

I just like the momentum holding up regardless of the selloff.

And will NVO get again above 85.00, that may look strong.

On the weekly chart, we will clearly see the chance to beneath the 200-week shifting common.

Plus, within the final 2 weeks, NVO has been buying and selling contained in the bar from 3 weeks in the past.

The month-to-month chart has its personal narrative. NVO-Monthly Chart

This chart has the 23-month and 80-month shifting averages.

Whereas the value is in the course of each shifting averages, notice the relative energy on the underside of the chart.

NVO on a month-to-month timeframe is massively oversold.

In the event you add the low threat illustrated on the weekly chart, together with the rising momentum and calendar ranges on the every day chart, that’s compelling sufficient.

{That a} scorching firm with good fundamentals is oversold is but one more reason to maintain this one in your radar.